Machine-learning prediction of heart damage from anthracycline or HER2 cancer therapies
Official title: Machine Learning Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER-2-Targeted Therapies
Run by University Hospital, Caen · NCT07191730 · Data updated 2026-11-12
We will see if a machine-learning score can predict which adults starting anthracycline or HER2-targeted cancer therapies will develop heart damage within one year.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | University Hospital, Caen Academic / other |
| Locations | 1 site (Caen) |
| Status | Recruiting |
| Started | October 29, 2025 |
| Main results expected | March 2028 |
| Study ends | November 2028 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT07191730 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) who are starting or planning anthracycline and/or HER2-targeted therapy and who will have baseline pre-treatment follow-up in a participating French cardio-oncology clinic are ideal candidates.
✕Probably not a fit
People not receiving anthracyclines or HER2-targeted therapies, those without French national health insurance, or patients whose 12-month follow-up will occur outside the enrolling center are unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, multicenter observational cohort in 15 French centers enrolling 600 patients treated with anthracyclines or HER2-targeted agents in cardio-oncology clinics. Patients receive a baseline pre-treatment evaluation and standardized data collection via a dedicated software platform that supports integration of AI tools. Machine learning methods will be used to develop a one-year prediction score for cancer therapy-related cardiotoxicity with the primary endpoint defined according to 2022 ESC criteria. Participants will be followed for 12 months to train and validate models and identify clinical and treatment-related predictors of cardiotoxicity.
Why it matters
Potential benefit: If successful, the score could help clinicians identify patients at high risk of therapy-related heart damage so monitoring and preventive care can be personalized.
How similar studies have gone: Machine-learning approaches to predict cardiotoxicity are emerging but currently have limited and mixed evidence, so this application remains relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Planned follow-up in cardio-oncology clinic as part of a baseline pre-treatment evaluation before a sequence of anthracycline and/or HER2-targeted therapy, according to the 2022 ESC recommendations * Inclusion regardless of prior exposure to potentially cardiotoxic anticancer therapies or thoracic radiotherapy Exclusion Criteria: * Patients not covered by the French national health insurance system (Sécurité Sociale) * Patients for whom 12-month follow-up is planned outside the center performing the baseline pre-treatment evaluation
Where it's running
-
CHU de Caen
Caen, France Recruiting
Study contacts
- Study coordinator: Damien Legallois, MD, PhD
- Email: damien.legallois@unicaen.fr
- Phone: 33231064418
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
AI-based assessment of heart function using ECG wearable monitors
This study tests if a new AI tool using a wearable heart monitor can accurately check heart function in people with heart failure compared to traditional heart scans.
-
Exercise and fitness program for breast cancer survivors to improve heart health
This study tests whether a special exercise and yoga program can help breast cancer survivors over 60 improve their heart health and physical fitness after treatment.
-
Stopping heart failure medications in cancer survivors with heart dysfunction
This study is testing if cancer survivors with improved heart function can safely stop taking their heart failure medications to see if it reduces their pill burden and side effects.
-
Biennial contrast-enhanced mammography for women with a history of breast cancer
This study is testing if using a special type of mammogram every two years along with yearly 3D breast scans can help women with a history of breast cancer find any new cancers more effectively than just the yearly scans alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.